Hetero announces the approval and launch of ‘COVIFOR’(Remdesivir) in India for the treatment of Covid-19

Hyderabad,India;21stJune2020: Hetero,one of India’sleading generic pharmaceutical companies,announced today that it has received the manufacturing and marketing approval for the investigational antiviral medicine‘Remdesivir’ from the Drug Controller General of India(DCGI) for the treatment of Covid-19. Hetero’s generic version of Remdesivir will be marketed under the brand name‘COVIFOR ’in India.Dr.B.ParthaSaradhiReddy,Chairman,Hetero Group of Companies,commented:“In the light of increasing COVID-19 cases in India,theapproval of‘COVIFOR’(Remdesivir)can prove to be a game-changer given its positive clinical outcomes.Backed by strong backward integration capabilities,we can ensure that the product is immediately made available to patients across the country.We are prepared forensuring enoughstocks required to cater to the present needs.We will continue to work closely with the government and medical communityto make a difference in the fightagainst COVID-19.This product is made indigenously inline with‘MakeinIndia’campaign as envisioned by our Hon’blePrimeMinister.”The drug‘Remdesivir’has been granted approval byDCGIfor the treatment of suspected or laboratory-confirmed casesofCOVID-19in adults and children,hospitalized with severe symptoms of the disease.COVIFOR(Remdesivir) willbeavailablein100mgvial(Injectable)which has tobe administered intravenously inahospital setting under the supervision ofa health care practitioner.The product is launched underalicensing agreement with GileadSciencesInc.to expand accesstoCOVID-19 treatment in low and middle-income countries.